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Highlights
• This study demonstrates that of brown adipose tissue (BAT) with CL316,243
attenuates the progress of diabetic kidney disease (DKD).
• Mechanistically, the activation of BAT improved concentrations of circulating
adipokines and microRNAs, which further affected the diabetic kidney and
reactivated the AMP-activated protein kinase/sirtuin 1/peroxisome proliferator-
activated receptor-γ coactivator-1α signaling pathway.
• The data suggest that BAT activation could be a novel therapeutic approach in the
treatment of DKD.
Abstract
Background: Brown adipose tissue (BAT) has been regarded as a potential target
organ to combat obesity and related metabolic disorders. However, the effect of
BAT activation on the development of diabetic kidney disease (DKD) remains
unclear.
Methods: Diabetic mice were induced by streptozotocin (STZ) combined with a
high-fat diet. To activate BAT, mice were administered 1 mg/kg per day, i.p.,
CL316,243, a β3-adrenergic receptor agonist, for 4 weeks. Blood glucose, serum
lipids, adipokines, 24-hour urinary albumin, 8-hydroxydeoxyguanosine (8-OHdG),
and circulating microRNA (miRNA) levels were analyzed, in addition to renal
pathology. Histological changes (fibrosis, inflammation) were evaluated in the
kidneys, as was the expression of oxidative stress-related genes. Renal signaling
pathways (fibroblast growth factor [Fgf]21/β-klotho/FGF receptor 1c and AMP-
activated protein kinase[AMPK]/sirtuin 1 [Sirt1]/peroxisome proliferator-
activated receptor-γ coactivator-1α [Pgc1α]) were also evaluated.
Results: Compared with untreated STZ-diabetic mice, CL316,243 treatment
reduced blood glucose, albeit not significantly (20.58 ± 3.55 vs 23.60
± 3.90 mM), and significantly decreased triglycerides and low-density lipoprotein
cholesterol and increased high-density lipoprotein cholesterol. Simultaneously,
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BAT activation significantly decreased 24-hour urinary albumin (34.21 ± 6.28 vs
70.46 ± 15.81 μg/24 h; P < 0.05) and 8-OHdG, improved renal fibrosis, inflam-
mation, and oxidative stress, and ameliorated renal morphological abnormalities. In
addition to enhancing BAT activity, CL316,243 significantly increased serum
adiponectin concentrations and renal Fgf21 sensitivity, and reactivated the renal
AMPK/Sirt1/Pgc1α signaling pathway. Furthermore, CL316,243 treatment
increased levels of some circulating miRNAs and downregulated expression of
their target genes in the kidney.
Conclusions: Activating BAT could improve kidney injury in diabetic mice via
metabolic improvements and renal AMPK activation by beneficial adipokines and
miRNAs.
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1 | INTRODUCTION
Diabetic kidney disease (DKD) is one of the major causes of
end-stage renal disease (ESRD). Current treatments, includ-
ing various pharmacological strategies and changes in life-
style, are only partially effective in preventing progression
of DKD.1 It is very important to explore new targets to
improve the outcomes.
Lipotoxicity has been implicated in the pathophysiology
of DKD.2 Recent studies have shown that various
adipokines, such as adiponectin and fibroblast growth factor
(FGF) 21, are involved in the regulation of renal metabo-
lism.3 In addition, adipose-derived circulating microRNAs
(miRNAs) have been demonstrated to regulate the metabo-
lism of other tissues.4 Various miRNAs play an important
role in the kidney.5 These findings reveal that adipose tissue
may be closely related to the development of DKD. Unlike
white adipose tissue, brown adipose tissue (BAT) is a
mitochondria-rich tissue that is specialized in non-shivering
thermogenesis through consumption of fatty acids and glu-
cose.6 Many previous rodent studies have revealed that acti-
vation of BAT for 4 weeks can regulate energy metabolism
and glucose homeostasis.7,8 In 2009, BAT was found to be
functional in adult humans,9 and was recently proved to be
activated in humans by β3-adrenergic receptor agonists.10
Activation of BAT has been considered to be associated
with immunity against obesity, diabetes, and related meta-
bolic diseases.11 In addition, as an endocrine organ, BAT
can secrete adipokines to regulate metabolism.12 Chronic
stimulation of BAT for 30 days also contributes to the
release of adipokines, which have beneficial effects on the
kidneys.13,14 Together, these findings suggest that activation
of BAT may have beneficial effects in preventing the
development of DKD. However, the relationship between
BAT and DKD has not been reported before.
In the present study we administered the β3-adrenergic
receptor agonist CL316,243 to stimulate BAT in type 2 dia-
betic (T2D) mice to investigate the effects of BAT activation
on kidney disease. Our hypothesis was that BAT activation
would attenuate the development of DKD by improving
metabolism and increasing levels of beneficial adipokines
and miRNAs, which could activate downstream signaling
pathways in the kidney.
2 | METHODS
2.1 | Animals
Male C57BL/6J mice, aged 6 weeks (n = 30), were pur-
chased from Guangdong Medical Laboratory Animal Center
(Guangzhou, China). All animals were maintained in a spe-
cific pathogen-free (SPF) barrier facility at Southern Medical
University (Guangzhou, China). Mice were kept at 22C
under a 12-hour light-dark cycle and had free access to water
and diet. All animal experiments were conducted in accor-
dance with the regulation of the Animal Care and Use Com-
mittee of the Southern Medical University.
2.2 | Induction of the diabetic mouse model
and CL316,243 treatment
Mice were randomly divided into two groups and fed either
a chow diet (Control) or high-fat diet (HFD; 5.24 kcal/g;
60% kcal from fat, 20% kcal from carbohydrate; Guangdong
Medical Laboratory Animal Center). To induce hyperglyce-
mia, after 4 weeks of feeding the HFD, mice (n = 22)
received a single intraperitoneal injection of streptozotocin
CAI ET AL. 959
(STZ; 120 μg/g body weight in 10 mM sodium citrate
buffer, pH 4.5; S0130; Sigma, Shanghai, China),15 whereas
the mice in the Control group (n = 8) were injected with an
equivalent volume of citrate buffer. Mice were considered
diabetic when their blood glucose concentrations exceeded
250 mg/dL. At Week 8, diabetic mice (n = 18) were ran-
domly divided into two groups, a diabetic control group
(DM-Con; n = 9) and a diabetic group treated with the β3-
adrenergic receptor agonist CL316,243 (DM + CL; n = 9).
Mice in the DM + CL group were administered 1 mg/kg, i.
p., CL316,243 daily for 4 weeks, whereas mice in the DM-
Con group received saline only. Throughout the experiment,
the Control and diabetic mice were fed chow diet and the
HFD, respectively. Food intake, body weight, and blood glu-
cose were measured every week. At Week 12, blood was
collected from the left ventricle under anesthesia (sodium
pentobarbital of 50 mg/kg through intraperitoneal injection)
after 4 hours of fasting; serum was stored at −80C until
analysis. Mice were killed by cervical dislocation, and adi-
pose tissues and kidneys were harvested and immediately
frozen in liquid nitrogen until further analysis.
2.3 | Assessment of renal function, oxidative
stress, and Fgf21 concentrations
At Weeks 8, 10, and 12, mice were placed individually in met-
abolic cages to collect 24-hour urine samples. Urinary albumin
and 8-hydroxydeoxyguanosine (8-OHdG) concentrations were
measured by ELISA (Bethyl Laboratories, Montgomery,
Texas; Cusabio, Barksdale, USA, respectively). Serum creati-
nine (Cr) was measured using a commercially available kit
(Nanjing Jiancheng Bioengineering Institute, Nanjing, China),
and FGF21 protein in the renal cortex was determined by
ELISA (Elabscience Biotechnology, Wuhan, China).
2.4 | Measurement of serum parameters
During the experiment, random blood glucose levels were mea-
sured using an Accu-Chek glucose monitor (Roche, Shanghai,
China). Serum adiponectin and Fgf21 concentrations were deter-
mined by ELISA (Elabscience Biotechnology). Triglycerides
(TG), high-density lipoprotein cholesterol (HDL-C) and low-
density lipoprotein cholesterol (LDL-C) were measured using
commercially available kits (Nanjing Jiancheng Bioengineering
Institute).
2.5 | Extraction of ribonucleic acid (RNA) and
quantitative real-time polymerase chain
reaction (qRT-PCR)
The renal cortex and adipose tissues were snap frozen in liq-
uid nitrogen, and RNA was extracted with TRIzol (Takara,
Dalian, China). The quality of the RNA was determined
using a NanoDrop ND-1000 Spectrophotometer (Thermo
Fisher Scientific, Waltham, Massachusetts). The cDNA was
synthesized by using an M-MLV Kit (Invitrogen, Carlsbad,
California). Real-time quantitative polymerase chain reac-
tion (qPCR) was performed in a Roche Lightcycler 480II
(Roche, Basle, Switzerland) using a SYBR Green qPCR Kit
(Takara). Relative gene expression was calculated using the
2−ΔΔCt method and 18 s as an internal control.16 The primers
used are listed in Table 1.
2.6 | Isolation of miRNAs and real-time qPCR
Serum total RNA was isolated using the miRcute serum/plasma
miRNA isolation kit (TianGen, Beijing, China) and reverse
transcribed using a miRNA First-Strand cDNA Synthesis kit
(TianGen) according to the manufacturer's instructions. Because
of the the lack of a stable endogenous serum miRNA, samples
were spiked with a synthetic Caenorhabditis elegans mir-39
miRNA mimic (cel-mir-39) as a control to monitor changes in
RNA recovery. The real-time qPCR was performed in a Roche
LightCycler480II using the miRcute miRNA Detection Kit
(TianGen). Relative expression of target miRNAs was calcu-
lated using the comparative 2-ΔΔCt method with external con-
trol. In virtue of the lack of a stable endogenous serum miRNA,
samples were spiked with a synthetic C. elegans mir-39
miRNA mimic (cel-mir-39) as a control to monitor changes in
RNA recovery. cel-mir-39 was the external control. Primers for
miR-26a, miR-30b, miR-30c, miR99a, miR100, miR181a, and
the external control were designed by the authors. Primer
sequences of these miRs as follows:miR-30b-5p: 5'-GC
GTCCTGTAAACATCCTACACTCAGCT-3'miR-99a-5p: 5'-
GCGTAACCCGTAGATCCGATCTTGTG-3'miR-100-5p: 5'-
GCGTAACCCGTAGATCCGAACTTGTG-3'miR-181a-5p: 5'-G
CGTCCAACATTCAACGCTGTCGGTGAGT-3' The universal
reverse primer and primers for miR-26a and miR-30c were
purchased from TianGen (Beijing, China).
2.7 | Western blotting
Total protein from the renal cortex and adipose tissues was
extracted using RIPA Lysis Buffer (Beyotime, Shanghai,
China), and protein concentrations were measured by the
bicinchoninic acid assay (Takara). Proteins (40 μg) were
electrophoresed by 10%-15% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (Bio-Rad, Hercules, Cal-
ifornia) and then transferred to polyvinylidene difluoride
membranes (Merck Millipore, Billerica, Massachusetts).
After membranes had been blocked, with 5% non-fat milk or
5% BSA they were hybridized overnight at 4C with primary
antibodies against transforming growth factor (Tgf)-β1
(1: 500 dilution; Santa Cruz Biotechnology, Santa Cruz,
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California), collagen 1 (Col1; 1:200 dilution; Abcam, Cam-
bridge, MA), fibronectin (Fn; 1: 500 dilution; R&D, Minne-
apolis, MN), tumor necrosis factor (Tnf)-α (1: 500 dilution;
ABclonal, Boston, MA), NADPH oxidase 1 (Nox1; 1: 500
dilution; GeneTex, Irvine, CA), superoxide dismutase
1 (Sod1; 1: 200 dilution; Santa Cruz Biotechnology),
NAD(P)H dehydrogenase 1 (Nqo1; 1: 200 dilution; Santa
Cruz Biotechnology), phosphorylated (p-) AMP-activated
protein kinase (AMPK; 1: 1000 dilution; CST, Danvers,
MA), total AMPK (1: 500 dilution; CST), sirtuin 1 (Sirt1;
1: 2000 dilution; Abcam), peroxisome proliferator-activated
receptor-γ coactivator-1α (Pgc1α; 1: 1000 dilution; Novus
Biologicals, Littleton, CO), uncoupling protein 1 (Ucp1)
(1: 500 dilution; Santa Cruz Biotechnology), and β-actin
(1: 500; ZSGB-BIO, Beijing, China). The membranes were
then incubated with an appropriate horseradish peroxidase-
conjugated secondary antibody for 1 hour, whose signal was
visualized using enhanced chemiluminescence (ECL)
reagents (Tanon, Shanghai, China) and quantified by
GelPro32 (Media Cybernetics, Silver Springs, MD, USA).
The membranes were washed for 3 times(8 minutes per
time) with Tris-buffered saline containing 0.1% Tween-20
(TBST) after the overnight incubation with the primary anti-
bodies.Then the membranes were incubated with secondary
antibody.
2.8 | Histological examination
Renal tissues were fixed for 48 hours with 4% parafor-
maldehyde, dehydrated, embedded in paraffin, and cut
into 4-μm slices, before being stained with periodic acid-
Schiff (PAS) and Masson's trichrome to assess mesangial
matrix expansion and collagen deposition, respectively.
More than 25 glomeruli per group were counted, and the
mean was used for analysis. All sections were evaluated
TABLE 1 Primer sequences used for real-time quantitative polymerase chain reaction
Gene name Gene symbol Primers (50-30)
Fibronectin Fn Forward: TAGCCCTGTCCAGGAGTTCA
Reverse: CTGCAAGCCTTCAATAGTCA
Collagen 1 Col1 Forward: GCAGGAGGTTTCGGCTAAGT
Reverse: GCAACAAAGTCCGCGTATCC
Transforming growth factor-β1 Tgfβ1 Forward: CCACCTGCAAGACCATCGAC
Reverse: CTGGCGAGCCTTAGTTTGGAC
Tumor necrosis factor-α Tnfα Forward: CATCTTCTCAAAATTCGAGTGACAA
Reverse: TGGGAGTAGACAAGGTACAACCC
Interlekin-1β Il-1β Forward: GTCTTTCCCGTGACCTTC
Reverse: ATCTCGGAGCCTGTTAGTGC
Uncoupling protein 1 Ucp1 Forward: AGGCTTCCAGTACCATTAGGT
Reverse: CTGAGTGAGGCAAAGCTGATTT
Peroxisome proliferator-activated
receptor-γ coactivator-1α
Pgc1α Forward: CCCTGCCATTGTTAAGACC
Reverse: TGCTGCTGTTCCTGTTTTC
Cd36 Cd36 Forward: TGTGTTTGGAGGCATTCTCA
Reverse: TTTTGCACGTCAAAGATCCA
Adipose triglyceride lipase Atgl Forward: TGTGGCCTCATTCCTCCTAC
Reverse: TCGTGGATGTTGGTGGAGCT
Cytochrome c oxidase subunit 2 Cox2 Forward: CCATCCCAGGCCGACTAA
Reverse: AATTTCAGAGCATTGGCCATAGA
Klotho beta Klb Forward: CAGGCCCATTGTTACCTTGT
Reverse: CTCCAAAGGTCTGGAAGCAG
Fibroblast growth factor receptor 1c Fgfr1c Forward: AATACCACCGACAAGGAAATGG
Reverse: AGTTACCCGCCAAGCACGTA
18S Forward: AGCCTGCGGCTTAATTTGAC
Reverse: CAACTAAGAACGGCCATGCA
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under an Olympus (Tokyo, Japan) BX40 upright light
microscope.
2.9 | Statistical analysis
Data are expressed as the mean ± SEM. Two-tailed Stu-
dent's t tests were used to compare two independent groups,
and one-way analysis of variance (ANOVA) was used to
examine the significance of differences among three inde-
pendent groups. Dunnett's test or the least significant differ-
ence (LSD) test was used for multiple comparisons.
Statistical analyses were performed in SPSS 20.0 (IBM
Corp., Armonk, New York). P < 0.05 was considered
significant.
3 | RESULTS
3.1 | Effects of CL316,243 on metabolic
parameters in diabetic mice
Blood glucose concentrations were higher in diabetic than
Control mice (by approximately 3-fold). There was a non-
significant decrease in blood glucose concentrations in
mice in the DM + CL compared with DM-Con group
(20.58 ± 3.55 vs 23.6 ± 3.9 mM, respectively;
Figure 1A). As shown in Figure 1B, serum TG (1.32
± 0.19 vs 0.53 ± 0.02 mM) and LDL-C (1.00 ± 0.10 vs
0.21 ± 0.04 mM) concentrations were higher in the DM-
Con than Control group (P < 0.001), and this was
reversed by CL316,243 treatment (P < 0.01). In contrast,
serum HDL-C was higher in the DM + CL group than in
the Control and DM-Con groups (4.44 ± 0.28 vs 2.84
± 0.17 and 3.32 ± 0.23 mM, respectively; P < 0.01).
Kidney weight and the kidney weight/body weight ratio
were higher in the DM-Con group than in the Control and
DM + CL groups (P < 0.05; Table 2). In addition, food
intake was increased in the DM-Con group compared
with the Control group (P < 0.01). However, there was a
obvious increase in food intake in DM + CL group com-
pared with the Control and DM-Con groups (P < 0.01;
Table 2).
3.2 | Effects of CL316,243 on 24-hour urinary
albumin and 8-OHdG
Urinary albumin excretion was higher in diabetic than Con-
trol mice (by approximately 7fold). By 4 weeks after
CL316,243 treatment, there was a decrease in urinary albu-
min excretion in the DM + CL compared with DM-Con
group (34.21 ± 6.28 vs 70.46 ± 15.81 μg/24 h, respectively;
P < 0.05; Figure 2A). Consistent with the results above,
high level of urinary 8-OHdG in diabetic mice was
decreased by CL316,243 treatment significantly (P < 0.001;
Figure 2B).
3.3 | Effects of CL316,243 on interscapular
BAT and epididymal adipose tissues
There were decreases in both Ucp1 mRNA and protein in
the BAT of DM-Con compared with Control mice
(P < 0.05), and these levels were restored by CL316,243
treatment (Figure 3B,C). In addition, compared with DM-
Con group, CL316,243 treatment of diabetic mice increased
the expression of the mitochondrial and fatty acid
metabolism-related genes Pgc1α, Cd36, and adipose triglyc-
eride lipase (Atgl) in epididymal adipose tissue (Figure 3A).
FIGURE 1 Effects of CL316,243 on A, blood glucose and B, serum lipids in diabetic mice. Data are the mean ± SEM (n = 7-9 per group).
*P < 0.05, **P < 0.01, ***P < 0.001 compared with the control group; ††P < 0.01, †††P < 0.001 compared with the diabetic control (DM-Con)
group. DM + CL, diabetic mice treated with CL316,243; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;
TG, triglycerides
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3.4 | Systemic and renal adipokine expression
Serum adiponectin concentrations were lower in DM-Con
than Control mice, but were restored by CL316,243 treat-
ment (P < 0.01; Figure 4A). In contrast, serum Fgf21 con-
centrations were upregulated in DM-Con compared with
Control mice (P < 0.001), and were not affected by
CL316,243 treatment (Figure 4B). In renal cortical tissue,
Fgf21 protein expression was in accordance with serum con-
centrations (Figure 4C). Interestingly, there were signifi-
cantly increases in Fgf21-related components, including
β-klotho and FGF receptor1c (Fgfr1c), in DM-Con com-
pared with Control mice, which were abrogated by
CL316,243 treatment (P < 0.05; Figure 4D).
3.5 | Effects of CL316,243 on serum miRNAs
and related target genes in the kidney
Some circulating miRNAs, such as miR-26a, miR-30b,
miR-30c, miR-99a, miR-100, and miR-181a, were increased
in diabetic mice. Three of these miRNAs (miR-30b, miR-
30c, and miR-99a) were increased in the DM-CL group
compared with the other two groups (P < 0.05; Figure 5A).
Based on the present and previous studies,16-19 four (Ctgf,
Snail1, Nox4, Egr1) candidate related genes in the kidney
were identified and tested, namely connective tissue growth
factor (Ctgf), snail family zinc finger 1 and early growth
response factor 1 (Egr1), the 30-untranslated region of which
could be targeted by miR-26a, miR-30b, miR-30c, miR-99a,
and miR-181a. The renal expression of these target genes,
verified to be associated with renal fibrosis,20,21 was
suppressed by CL316,243 treatment compared with that in
the DM-Con group (P < 0.05; Figure 5B).
3.6 | Effects of CL316,243 on renal fibrosis,
inflammation, and oxidative stress-related
molecules
The mRNA expression of fibrotic markers, namely Tgfβ1,
Col1, and Fn, and inflammatory markers, namely Tnfα and
TABLE 2 Biochemical and physical parameters of experimental animals at Week 12
Parameters Control DM + CL DM-Con
BW (g) 29.91 ± 0.97 30.51 ± 0.55 29.24 ± 0.70
KW (g) 0.20 ± 0.02 0.22 ± 0.01† 0.27 ± 0.02**
KW/BW (×10−3) 6.40 ± 0.42 6.94 ± 0.37†† 9.03 ± 0.49**
RBG (mM)2 8.30 ± 0.46 20.58 ± 3.55* 23.6 ± 3.87**
Food intake (kcal/day per mouse) 11.82 ± 0.31 18.92 ± 0.80***,†† 15.72 ± 0.50**
Serum Cr (μM) 22.79 ± 6.79 23.4 ± 5.43 24.65 ± 5.25
Urine volume (mL) 1.84 ± 0.22 2.77 ± 1.20† 11.50 ± 2.09*
Data are the mean ± SEM (n = 7–9 per group).
BW, body weight; Cr, creatinine; DM + CL, diabetic mice treated with CL316,243; KW, kidney weight; RBG, random blood glucose.
*P < 0.05; **P < 0.01; ***P < 0.001 compared with the control (normal) group; †P < 0.05; ††P < 0.01 compared with the diabetic control (DM-Con) group.
FIGURE 2 Effects of CL316,243 on 24-h urinary A, albumin excretion and B, 8-hydroxydeoxyguanosine (8-OHdG) concentrations in
diabetic mice. Data are the mean ± SEM (n = 7-9 per group). *P < 0.05, **P < 0.01, ***P < 0.001 compared with the control group; †P < 0.05,
††P < 0.01, †††P < 0.001 compared with the diabetic control (DM-Con) group. DM + CL, diabetic mice treated with CL316,243
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Il-1β, was increased in DM-Con compared with Control
mice (P < 0.05; Figure 6A). Furthermore, western blotting
assays revealed that protein levels were consistent with
mRNA expression (Figure 6B–F). However, the increased
production of Tgfβ1, Col1, Fn, and Tnfα observed in DM-
Con mice was significantly attenuated by CL316,243 treat-
ment (P < 0.05; Figure 6B–F).
Western blotting analysis showed that Sod1 and Nqo1
levels were reduced in DM-Con compared with Control
mice, but that CL316,243 treatment enhanced renal Sod1
and Nqo1 expression (P < 0.05; Figure 6B,H–I). Expression
of renal NADPH oxidase 1 (Nox1) was increased in DM-
Con compared with Control mice, and was reduced by
CL316,243 treatment (P < 0.05; Figure 6B,G).
3.7 | Effects of CL316,243 on renal
histological changes
More serious collagen accumulation was observed in DM-
Con than Control mice, which was improved by CL316,243
treatment (P < 0.001; Figure 7B,D). Similarly, there was an
increase in fractional mesangial area in DM-Con compared
with Control mice, and the mesangial expansion was obvi-
ously improved in the CL316,243-treated group (P < 0.001;
Figure 7A,C).
3.8 | Renal expression of p-AMPK (Thr172),
total AMPK, Sirt1, and Pgc1α
As shown in Figure 8, the ratio of p-AMPK (Thr172)/total
AMPK and Sirt1 and Pgc1α levels were markedly decreased
in DM-Con compared with Control mice (P < 0.05). How-
ever, the CL316,243 treatment reversed the decreases in the
p-AMPK (Thr172)/total AMPK ratio and Sirt1 and Pgc1α
levels.
4 | DISCUSSION
In the present study we verified the beneficial renal effects
of BAT activation in diabetic mice, which were mediated by
improvements in systemic and renal metabolism. Chronic
stimulation of BAT did not improve glycemic control in dia-
betic mice, as reported previously.8 This apparent
FIGURE 3 Effects of CL316,243 on relative mRNA expression of A, mitochondrial and thermogenic genes in epididymal adipose tissues
(EP) and B, Ucp1 in interscapular brown adipose tissue (BAT) in diabetic mice. Control, non-diabetic mice; DC-Con, diabetic control mice;
DM + CL, diabetic mice treated with CL316,243; Pgc1α, peroxisome proliferator-activated receptor-γ coactivator-1α; Atgl, adipose triglyceride
lipase; Cox2, cytochrome oxidase subunit 2; Cd36, cluster of differentiation 36. C Representative western blot for Ucp1 protein in interscapular
BAT and D, densitometric analysis. Data are the mean ± SEM (n = 7-9 per group). *P < 0.05, **P < 0.01 compared with Control; †P < 0.05,
††P < 0.01 compared with the DM-Con group. aP = 0.074, bP = 0.072 compared with Control
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discrepancy may be due to differences in animal models and
interventions. In addition, in contrast to expectations, the
body weight of DM-Con mice was not higher than that of
Control mice in the present study, whereas the body weight
of CL316,243-treated mice exhibited a tendency to be
greater than that of DM-Con mice at the end of the study.
FIGURE 4 Effects of CL316,243 on serum adipokines (adiponectin and fibroblast growth factor [FGF] 21) and renal expression of Fgf21
components in diabetic mice. A, Serum adiponectin and B, serum Fgf21 concentrations; C, Fgf21 protein and D, relative expression of β-klotho
(Klb) and FGF receptor 1c (Fgfr1c) mRNA in renal cortical tissues. Data are the mean ± SEM (n = 6 per group). *P < 0.05, **P < 0.01,
***P < 0.001 compared with control (non-diabetic) mice; †P < 0.05, ††P < 0.01 compared with the diabetic control (DM-Con) group. DM + CL,
HFD combined with STZ-induced diabetic mice treated with CL316,243
FIGURE 5 Effects of CL316,243 on serum microRNAs (miR) and renal expression of target genes in diabetic mice. A, Relative expression of
miR-26a, miR-30b, miR-30c, miR-99a, miR-100 and miR-181a extracted from the serum of non-diabetic (Control), streptozotocin-induced diabetic
(DM-Con), and CL316,243-treated diabetic (DM + CL) mice. B, Relative mRNA expression of connective tissue growth factor (Ctgf), Snail1,
Nox4, and early growth response factor 1 (Egr1) in renal cortical tissues. Data are the mean ± SEM (n = 6 per group). *P < 0.05, **P < 0.01,
***P < 0.001 compared with Control; †P < 0.05, ††P < 0.01 compared with the DM-Con group
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FIGURE 6 Legend on next coloumn.
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This may be due to a variety of factors, including uncon-
trolled diabetic disorders, long-term HFD feeding, and
drug-induced metabolic improvements and increased food
intake. Conversely, Bartelt et al.22 confirmed that activa-
tion of BAT could correct hyperlipidemia by modulating
vascular lipoprotein homeostasis. In the present study,
CL316,243-treated mice also exhibited changes in lipid
profiles, including decreased serum TG and LDL-C
concentrations.
In terms of DKD, we provide direct evidence that BAT
activation significantly ameliorates albuminuria, renal fibro-
sis, and structural changes. In addition, CL316,243 treatment
exhibited renal protective effects by improving in oxidative
stress and inflammatory cytokines in the kidney. To further
elucidate the potential mechanism independent of blood glu-
cose control, we first detected the activity of interscapular
BAT and epididymal adipose tissue. Numerous preclinical
and clinical studies have reported that the role of BAT
FIGURE 6 Fibrosis, inflammation, and oxidative stress-related molecules in the renal cortex of non-diabetic (Control), streptozotocin-induced
diabetic (DM-Con), and CL316,243-treated diabetic (DM + CL) mice. A, Relative expression of the mRNA of renal fibrotic and inflammatory
molecules. Tgf-β1, transforming growth factor-β1; Col1, collagen 1; Fn, fibronectin; Tnfα, tumor necrosis factor-α; IL-1β, interleukin-1β. B,
Representative western blot showing Fn, Col1, Tgf-β1, Tnf-α, NADPH oxidase 1 (Nox1), NAD(P)H dehydrogenase 1 (Nqo1), superoxide
dismutase 1 (Sod1), and β-actin. C-I, Densitometric analysis of western blotting results. Data are the mean ± SEM (n = 6 per group). *P < 0.05,
**P < 0.01, ***P < 0.001 compared with Control; †P < 0.05, ††P < 0.01 compared with the DM-Con group. aP = 0.089 compared with the DM-
Con group
FIGURE 7 Renal histological changes in non-diabetic (Control), streptozotocin-induced diabetic (DM-Con), and CL316,243-treated diabetic
(DM + CL) mice. A,B, Representative images of periodic acid-Schiff (PAS) and Masson's trichrome (Masson) staining of renal sections from
Control, DM-Con, and DM + CL mice. Bars, 10 μm. C, Mesangial expansion and D, collagen accumulation in PAS- and Masson-stained slices,
respectively, as quantified using Image-Pro Plus 6.0 software (Media Cybernetics, Silver Springs, MD). Data are the mean ± SEM (n = 6 per
group). *P < 0.05, **P < 0.01, ***P < 0.001 compared with Control; †††P < 0.001 compared with the DM-Con group
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gradually deteriorates in the development of obesity and dia-
betes.23,24 In accordance with these data, we found that the
expression of BAT-specific and fatty acid metabolism-
related genes was downregulated in diabetic mice and
restored by CL316,243 treatment. Next, we investigated
whether these beneficial effects were mediated by BAT-
secreted adipokines. Increasing evidence suggests that
adiponectin reduces microalbuminuria and exerts ren-
oprotective effects in diabetic animals.25 The mechanism
appears to be related to AMPK activation and an
angiotensin-antagonistic effect.26,27 In addition, low
adiponectin levels in T2D patients are predictive of progres-
sion of DKD.28 These findings are in agreement with the
changes we observed in serum adiponectin concentrations
observed in the present study. The potential mechanism
may include the secretion of beneficial adipokines by
refreshed BAT that then act on the kidney. Hondares et al.13
recently reported that BAT could synthesize and secret
Fgf21 after thermogenic activation. Elevated serum Fgf21
concentrations may be a useful indicator of kidney disease
progression.29 In the present study, we also observed a mar-
ked increase in serum Fgf21 concentrations in diabetic mice,
suggesting that our diabetic model is an FGF21-resistant
state. However, there was no change in serum FGF21 con-
centrations after BAT activation. To further explore how
Fgf21 could act in the kidney, we tested Fgf21-related com-
ponents, such as β-klotho and Fgfr1c. Interestingly,
Fgf21-related components in the kidneys were markedly
reduced following activation of BAT, suggesting that BAT
activation enhances the sensitivity to Fgf21.
In eukaryotes, AMPK is a crucial kinase that primarily
regulates energy metabolic homeostasis.30 Both
adiponectin and Fgf21 can activate the AMPK signaling
pathway.26,31 In the present study, we demonstrated that
CL316,243 treatment activated the AMPK/Sirt1/Pgc1α axis
in the diabetic kidney. Accumulating data indicates that
FIGURE 8 Phosphorylated (p-) AMP-activated protein kinase (AMPK) (Thr172), total AMPK, sirtuin 1 (Sirt1) and peroxisome proliferator-
activated receptor-γ coactivator-1α (Pgc1α) levels in the renal cortex of non-diabetic (Control), streptozotocin-induced diabetic (DM-Con), and
CL316,243-treated diabetic (DM + CL) mice. A, Representative western blots for p-AMPK (Thr172), total AMPK, Sirt1, Pgc1α, and β-actin in renal
cortical tissues. B-D, Densitometric analysis of western blotting results. Data are the mean ± SEM (n = 6 per group). *P < 0.05, **P < 0.01
compared with Control; †P < 0.05 compared with DM-Con
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activation of the AMPK/Sirt1/Pgc1α pathway prevents
inflammation and oxidative stress by inhibiting the nuclear
factor-κB pathway and promoting fatty-acid β-oxidation, as
well as the expression of antioxidants.32-34 In addition,
AMPK acts as an antifibrotic by reducing Nox4/Tgf-β1 sig-
naling.35 These possible mechanisms finally result in anti-
oxidative stress, anti-inflammatory, and antifibrotic effects
in the diabetic kidney following CL316,243 treatment.
Recently, BAT was reported to regulate hepatic metabo-
lism by secreting miRNAs.4 Coincidentally, miRNAs also
play vital roles in the development of DKD.36 The miRNAs
may be another key medium between BAT and kidney. In
the present study, BAT activation significantly upregulated
some serum miRNAs and downregulated the renal expres-
sion of their related target genes, which are involved in the
pathogenesis of DKD. In the present study we only focused
on the mediums between BAT and the kidney, and we will
explore the mechanisms by which these mediums act on the
kidneys in the near future.
In summary, BAT activation has beneficial renal effects
in diabetic mice by improving metabolic and activating renal
AMPK/Sirt1/Pgc1α signaling pathways. This may be medi-
ated by effects of circulating BAT-derived adipokines and
miRNAs on the kidney.
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